Scarica l'app Stockscreener
0.1878
1.16%
-0.0022
Dopo l'orario di chiusura:
.34
0.1522
+81.04%
Liminatus Pharma Inc Borsa (LIMN) Ultime notizie
Liminatus Pharma Announces Merger Agreement with InnocsAI LLC to Expand CAR-T Therapy Technologies - Minichart
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Liminatus Pharma to Acquire InnocsAI in Stock Deal, 1.6B Shares at $0.20 Plus CVRs - TradingView
LIMN Should I Buy - Intellectia AI
Liminatus Pharma 1Q 2026: Net loss $1.12M, Diluted EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Liminatus Pharma (NASDAQ: LIMN) Q1 loss, going concern and Nasdaq listing risks - Stock Titan
TradingKey - TradingKey
Why Liminatus (LIMNW) is still under the radar (+33.11%) 2026-05-11Sector Leader - Newser
The key risks discussed in Liminatus Pharma (LIMN) earnings | LIMN QX Earnings: Liminatus Pharma Reports No Revenue, Pipeline FocusHigh Attention Stocks - newser.com
LIMN QX Earnings: Liminatus Pharma Reports No Revenue, Pipeline FocusMacro Risk - newser.com
What Liminatus (LIMNW) disclosed about workforce costs | LIMNW: Liminatus Warrants Report No Earnings DataLiquidity Risk - Newser
Net current asset value per share of Liminatus Pharma, Inc. – NASDAQ:LIMN - TradingView
LIMNW Price History for Liminatus Pharma Warrants Stock - Barchart.com
Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance - MSN
Is Liminatus (LIMNW) stock trending down today | Liminatus Posts No Financials, Pipeline Drives Warrant MovesHigh Growth - newser.com
Is Liminatus Pharma (LIMN) stock worth buying today Earnings ReportPricing Power - Xã Châu Thành
LIMNW (Liminatus Pharma) Cyclically Adjusted Price-to-FCF : (As of Apr. 22, 2026) - GuruFocus
LIMNW (Liminatus Pharma) PB Ratio : (As of Apr. 21, 2026) - GuruFocus
LIMNW (Liminatus Pharma) Cyclically Adjusted PB Ratio : (As of Apr. 21, 2026) - GuruFocus
Is Liminatus Pharma (LIMN) stock forming lower lows (Institutional Selling) 2026-04-20Social Flow Trades - Cổng thông tin điện tử tỉnh Lào Cai
Liminatus Pharma (LIMN) Stock: Is It Overvalued vs Peers (Bearish Sentiment) 2026-04-18Reward Analysis - Xã Thanh Hà
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionAcurx Pharmaceuticals (NASDAQ:ACXP), Ali - Benzinga
Quarterly Recap: What is the cash position of Liminatus Pharma Inc2026 Trade Ideas & Free Reliable Trade Execution Plans - baoquankhu1.vn
Earnings Report: Is Liminatus Pharma Inc Equity Warrant stock undervalued right nowTrade Volume Report & Verified Stock Trade Ideas - baoquankhu1.vn
Resistance Check: Can INNOVATE Corp stock outperform in a bear marketEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
What is the sentiment around Liminatus Pharma (LIMN) Stock | Price at $0.18, Down 1.13%Hot Stocks - Newser
Quarterly Earnings: Can NRDS be recession proofGlobal Markets & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Update Recap: Will SOBR outperform during market rallies2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Breakout Move: Can Liminatus Pharma Inc Equity Warrant reach resistance levels soonFed Meeting & Weekly Top Performers Watchlists - baoquankhu1.vn
LIMN Rebounds Close to Support Level, Yet Downward Trend Remains Firm - Bitget
Is Liminatus Pharma (LIMN) Stock a Safe Investment | Price at $0.19, Up 6.29%Smart Money Flow - Newser
Growth Value: Is Liminatus Pharma Inc forming a breakout pattern2026 Patterns & Entry Point Strategy Guides - baoquankhu1.vn
Retail Trends: Whats the fair value of Liminatus Pharma Inc Equity Warrant stock2026 Intraday Action & Weekly Sector Rotation Insights - baoquankhu1.vn
Liminatus Pharma 2025 Annual Report: Pre-Clinical Cancer Therapy Pipeline, Strategy, and Risk Overview - Minichart
Liminatus Pharma 2025 10-K — $0 Revenue, Net Loss $10.21M - TradingView — Track All Markets
Liminatus Pharma (NASDAQ: LIMN) faces cash strain, dilution and Nasdaq listing risks - Stock Titan
Liminatus Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Insider Trends: Is Liminatus Pharma Inc stock a smart retirement pick2026 PreEarnings & Weekly Return Optimization Plans - baoquankhu1.vn
FOMO Trade: Is Liminatus Pharma Inc a good ESG investment2026 Momentum & Capital Efficient Trading Techniques - baoquankhu1.vn
Institution Moves: Is Liminatus Pharma Inc stock a top performer YTD2026 Buyback Activity & Stepwise Trade Execution Plans - baoquankhu1.vn
Liminatus Pharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Jobs Data: What are the future prospects of Liminatus Pharma Inc Equity WarrantTrade Analysis Report & AI Driven Price Predictions - baoquankhu1.vn
Fundamentals Check: Is Liminatus Pharma Inc Equity Warrant subject to activist investor interest2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Moving Averages: What are Liminatus Pharma Incs recent SEC filings showingJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
LIMN Stock Price, Quote & Chart | LIMINATUS PHARMA INC-CL A (NASDAQ:LIMN) - ChartMill
Weekly Earnings: Is Liminatus Pharma Inc Equity Warrant stock undervalued right nowMarket Activity Summary & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Aug Patterns: Can BPMC maintain its current growth rate2026 Fundamental Recap & Accurate Technical Buy Alerts - baoquankhu1.vn
Liminatus eyes clinic with CD47-blockade antibody IBA-101 - BioWorld MedTech
Liminatus Pharma to initiate Phase 1 clinical trial for IBA101 antibody - TipRanks
Liminatus Pharma’s IBA101 May Represent the CD47 Innovation Addressing Anemia and Thrombocytopenia in Advanced Immuno-Oncology - Bitget
Liminatus Pharma announces planned phase 1 clinical trial of IBA101, a next-generation CD47 blocking antibody - marketscreener.com
2.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):